Clinical Outcomes Based on Measurable Residual Disease Status in Patients with Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis

Measurable residual disease (MRD) response during acute myeloid leukemia (AML) treatment is a gold standard for determining treatment strategy, especially in core-binding factor (CBL) AML. The aim of this study was to critically review the literature on MRD status in the CBF-AML to determine the ove...

Descripción completa

Detalles Bibliográficos
Autores principales: Rotchanapanya, Wannaphorn, Hokland, Peter, Tunsing, Pattaraporn, Owattanapanich, Weerapat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711894/
https://www.ncbi.nlm.nih.gov/pubmed/33256157
http://dx.doi.org/10.3390/jpm10040250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711894/
https://www.ncbi.nlm.nih.gov/pubmed/33256157
http://dx.doi.org/10.3390/jpm10040250

Ejemplares similares